Growth-inhibitory_effect_of_combination_chemotherapy_for_human_pancreatic_cancer_cell_lines._Sensitivities_to_anti-tumor_drugs,_mitomycin_C_(MMC),_aclarubicin_hydrochloride_(ACR),_doxorubicin_hydrochloride_(ADR),_cisplatin,_and_5-fluorouracil_(5FU),_were_examined_using_PK-1,_-8,_-9,_-12,_-14,_and_-16_cell_lines_derived_from_human_pancreatic_cancer._These_cell_lines_showed_different_sensitivities_to_each_of_the_above_anti-tumor_drugs._The_concentrations_required_for_50%_growth-inhibition_(IC50)_after_2_hours_of_exposure_were_0.096_to_0.35_micrograms/ml_for_MMC,_0.0074_to_0.0076_micrograms/ml_for_ACR,_0.033_to_0.23_micrograms/ml_for_ADR,_0.35_to_1.9_micrograms/ml_for_cisplatin,_and_21_to_42_micrograms/ml_for_5FU,_IC50_of_each_anti-tumor_drug_decreased_significantly_after_48_hours_of_exposure._The_combination_of_any_two_out_of_MMC,_ACR,_and_5FU_showed_synergistic_inhibition_of_the_growth_of_PK-1_and_PK-8_cell_lines._These_results_show_that_MMC,_ACR,_ADR,_cisplatin,_and_5FU_have_sufficient_anti-tumor_effect_against_six_human_pancreatic_cancer_cell_lines_even_at_clinically_achievable_concentrations_and_exposure_times,_and_chemotherapy_for_pancreatic_cancers_requires_naturally_effective_drug_delivery_into_cancer_tissues.